Sophia Genetics cuts FY24 revenue view to $65M-$67M from $78M-$81M

Consensus $76.63M. Sees FY24 gross margins 73.2%. Sees FY24 operating loss $9.9M. Camblong added, “Looking ahead, we remain confident in our long-term growth and in the growth prospects of our end markets. Exciting catalysts such as the continued success of MSK-ACCESS(R) powered with SOPHiA DDM(TM), a suite of new applications launching this year, and refreshed momentum in our BioPharma business offer meaningful upside and give us conviction in a medium-term growth recovery.”